Phase II Study of Granulocyte-Macrophage Colony Stimulating Factor Plus Mitoxantrone for the Treatment of Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the effect of the combination of mitoxantrone and GM-CSF on time to progression in patients with hormone-refractory prostate cancer.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : GM-CSF
- drug : Mitoxantrone
Phase: Phase 2
Ages Eligible For Study:
- must give signed written informed consent - must be of age 18 years or older - must have histologically confirmed adenocarcinoma of the prostate - must have hormone-refractory prostate cancer - must have failed first-line docetaxel-containing regimen - must not have had any prior immunotherapy including, but not limited to, vaccines and GM-CSF - minimum PSA > 5mg/dL, and rising according to the PSA Consensus Criteria (i.e. progressive disease after androgen deprivation and during first-line docetaxel-based chemotherapy) - KPS > 60% - Life expectancy of greater than 6 months